Concepedia

Author

Amir Shojaei

Takeda (United States)

Also Known As

Amir Ahmad Shojaei, Amir Shojaei

20

Publications

710

Citations

9

H-Index

4

Concepts

All Affiliations

Takeda (United States)Cincinnati Eye InstituteUniversity of Alabama at BirminghamSall Research Medical Center
AS

About

Amir Shojaei is an author at Takeda (United States) specializing in pharmacokinetics, pharmacotherapy, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

38

2

Pharmacology

1

1

38

3

Pharmacokinetics

1

1

38

4

Pharmacotherapy

1

1

38

Amir Shojaei

×

7

Publications

406

Citations

7

H-Index

YearCitations

Lifitegrast for the Treatment of Dry Eye Disease

Edward J. Holland, Jodi Luchs, Paul Karpecki,

Ophthalmology

2016

196

Pharmacokinetics of a Guanfacine Extended‐Release Formulation in Children and Adolescents with Attention‐Deficit–Hyperactivity Disorder

Samuel W. Boellner, Michael Pennick, K.Suzanne Fiske,

Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy

2007

58

A phase i, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults

Dennis Swearingen, Michael Pennick, Amir Shojaei,

Clinical Therapeutics

2007

38

Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials

Edward J. Holland, Walter O. Whitley, Kenneth Sall,

Current Medical Research and Opinion

2016

36

Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease

Kelly K. Nichols, Eric D. Donnenfeld, Paul Karpecki,

European Journal of Ophthalmology

2018

36

Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial

Kelly K. Nichols, Edward J. Holland, Melissa Toyos,

Clinical ophthalmology

2018

22

Bioavailability of triple-bead mixed amphetamine salts compared with a dose-augmentation strategy of mixed amphetamine salts extended release plus mixed amphetamine salts immediate release

James Ermer, Amir Shojaei, Michael Pennick,

Current Medical Research and Opinion

2007

20

Page 1